Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Birmingham, Alabama

This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2004
Shown on this page
12
Current sort
Recently updated
Location scope
Birmingham, AL
Filters apply within this location only.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this location

These controls apply only within Birmingham, Alabama. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 1273–1284 of 2,004 matching trials in Birmingham, AL.
Indexed local directory records.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Birmingham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Stored official records

Open in full search
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016
View directory record Official record
Conditions
Relapsed/Refractory Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 31, 2026, 6:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival Graft and Acellular Dermal Matrix

NCT04920136
View directory record Official record
Conditions
Gingival Recession, Lack of Keratinized Attached Peri-implant Mucosa, Thin Gingiva
Interventions
Free Gingival graft, Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 30, 2026, 2:10 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
capecitabine, dextrose, liposomal doxorubicin, nab-paclitaxel, normal saline, paclitaxel, pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 5, 2026, 5:07 AM EST
Recruiting Phase 3 Interventional

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel, Pegylated liposomal Doxorubicin (PLD), Topotecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 7:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome

NCT07106359
View directory record Official record
Conditions
Cancer Prevention, Cascade Testing, Colorectal Cancer, Decision Making, Lynch Syndrome, Uterine Cancer
Interventions
Information Letter, Information Letter and Booklet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 27, 2026, 12:27 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

NCT03816358
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 5, 2026, 5:15 PM EST
Completed Phase 2 Interventional Results available

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT01708941
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
276
States / cities
Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 184 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 13, 2026, 6:25 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Placebo (matched to SUZ), Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 14, 2026, 4:08 PM EDT
Recruiting No phase listed Observational

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

NCT07091019
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
TKIs
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
17
States / cities
Birmingham, Alabama • Stockton, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 30, 2026, 8:04 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185
View directory record Official record
Conditions
Advanced Solid Tumor, Colorectal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
5Fluorouracil, Carboplatin, Cetuximab, Cisplatin, Gemcitabine, Irinotecan, LY4066434., Leucovorin, Nab paclitaxel, Oxaliplatin, Pembrolizumab, Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 13, 2026, 10:09 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Activated charcoal, Cholestyramine, Frexalimab, MRI contrast-enhancing agents, Placebo infusion, Placebo tablet, Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
99
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 6:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

NCT05194293
View directory record Official record
Conditions
Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Interventions
Durvalumab, Regorafenib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 9, 2026, 8:11 PM EDT